Tigecycline for Treatment of Pneumonia and Empyema Caused by Carbapenemase‐Producing Klebsiella pneumoniae
Authors:
- David J RiddleDRDavid J Riddle
- David J RitchieDRDavid J Ritchie
- 1 July 2007
- journal article
- case report
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 27 (7) , 1052-1057
Abstract
Strains of Klebsiella pneumoniae that produce one of three possible carbapenemases—KPC—have recently been identified with increasing frequency among isolates recovered from patients residing along the East Coast of the United States, particularly within the New York City metropolitan region. These strains have exhibited resistance to multiple antibiotic classes, including carbapenem agents. We report a case of nosocomial pneumonia and empyema caused by a KPC‐producing isolate of K. pneumoniae at a large midwestern U.S. tertiary care facility in which the patient was treated with tigecycline. Although the pneumonia was treated successfully, the empyema recurred in association with a treatment‐emergent tigecycline minimum inhibitory concentration (MIC) increase from 0.75 to 2 μg/ml. Clinicians should be aware of the potential occurrence of this treatment‐emergent MIC increase, especially in the setting of sustained tigecycline therapy. In addition, the emergence of carbapenem‐resistant Enterobacteriaceae reinforces the importance of antibiotic stewardship and strict infection control practices.Keywords
This publication has 21 references indexed in Scilit:
- Carbapenem Resistance inKlebsiella pneumoniaeNot Detected by Automated Susceptibility TestingEmerging Infectious Diseases, 2006
- Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolatesDiagnostic Microbiology and Infectious Disease, 2005
- In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004)Diagnostic Microbiology and Infectious Disease, 2005
- In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004)Diagnostic Microbiology and Infectious Disease, 2005
- Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumoniaDiagnostic Microbiology and Infectious Disease, 2005
- In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptidesJournal of Antimicrobial Chemotherapy, 2003
- Occurrence of Newer β-Lactamases in Klebsiella pneumoniae Isolates from 24 U.S. HospitalsAntimicrobial Agents and Chemotherapy, 2002
- Novel Carbapenem-Hydrolyzing β-Lactamase, KPC-1, from a Carbapenem-Resistant Strain ofKlebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2001
- Intravenous Colistin as Therapy for Nosocomial Infections Caused by Multidrug‐Resistant Pseudomonas aeruginosa and Acinetobacter baumanniiClinical Infectious Diseases, 1999
- Effects of Large Doses of Colistin Sulphomethate Sodium on Renal FunctionBMJ, 1970